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Background: Coronary stent deployment is a major advance in interventional treatment, but 20–40% of patients
still develop in-stent restenosis (ISR) due to neointimal hyperplasia. Genetic factors play a role in restenosis. This
study investigated the frequency of 5A/6A polymorphism in the promoter of the stromelysin-1 gene, and the issue
of whether it contributes to restenosis among patients receiving coronary stent in the Chinese population in Taiwan.
Methods: We investigated 344 symptomatic patients after successful coronary stent placement. All patients received
repeated angiography after 6 months, or earlier if clinically indicated. Angiographic restenosis was defined as * 50%
diameter stenosis at follow-up. Genotyping for stromelysin-1 promoter was based on a polymerase chain reaction technique.
Results: The stromelysin-1 gene promoter genotypes 5A5A, 5A6A, and 6A6A were distributed in 3.5%, 22.7%, and
73.8% of patients, respectively. The frequency of the 6A allele was 0.85. There was no significant difference in
angiographic ISR between the non-6A6A and 6A6A groups (28.9% and 37.0%, respectively, p = 0.165). However,
subgroup analysis revealed a significant difference in patients according to angina status. Among the 5A5A and
5A6A genotype groups, patients with unstable angina had significantly higher ISR rates than those with stable angina
(48% vs 21.5%, p = 0.013). On the other hand, among patients with stable angina, those with a 6A6A genotype
had a higher ISR rate than those with a non-6A6A genotype (p = 0.029), making the 6A6A genotype an independent
predictor of ISR (odds ratio, 2.57; 95% confidence interval, 1.22–5.41; p = 0.013).
Conclusion: There is a low frequency of the stromelysin-1 promoter 5A allele in the Chinese population in Taiwan.
How stromelysin-1 5A/6A polymorphism affects ISR appears to be linked to angina status. These results merit further
study to identify patients carrying genotypes which put them at increased risk of ISR, and which matrix metalloproteinase
inhibitors or drug-eluting stents are more effective for those at risk. [J Chin Med Assoc 2005;68(11):506–512]
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Introduction
Percutaneous coronary intervention (PCI) with stent
implantation significantly reduces the incidence of
complications and restenosis compared with balloon
angioplasty alone, via an improved post-procedure
luminal diameter and an abrogation of the constrictive
remodeling of the artery. However, stent-related arterial
injury results in intense inflammatory responses, lead-
ing to severe neointimal proliferation and matrix
accumulation, which, in 20–40% of patients, ends up
as clinically significant in-stent restenosis (ISR).1–3
Several angiographic and patient-related factors, such
as small coronary arteries, lesion complexity, the
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presence of diabetes mellitus and acute coronary
syndrome, have been identified to be associated with
ISR. However, these risk factors cannot fully explain
the complex process of ISR.4 Recent information
reveals that genetic factors play a role in the initiation
or progression of ISR.5
The matrix metalloproteinase (MMP) family and
their endogenous tissue inhibitors regulate the
accumulation of extracellular matrix, and thus
contribute to the rate of growth of atherosclerotic
plaques.6 Stromelysin-1, also known as MMP3, is a key
member of the MMP family, with wide substrate
specificity, degrading collagen types II, IV and IX,
proteoglycans, laminin, fibronectin, gelatins and elas-
tin, as well as having a role in activating other MMPs.
Its expression is primarily regulated at the level of
transcription.7,8 In addition, animal study revealed
that migration and proliferation of vascular smooth
cells and neointimal formation after vessel wall injury
of rat carotid arteries was substantially inhibited by
antisense oligonucleotides to stromelysin-1 mRNA.9
Thus, stromelysin-1 is a candidate for influencing
vascular remodeling, plaque formation and rupture,
and restenosis.
A common adenine  inser t ion/delet ion
polymorphism (5A/6A) at position –1171 of the
human stromelysin-1 gene promoter (National
Center for Biotechnology Information SNP
identification number rs3025039) influences
transcription factor binding and stromelysin-1
promoter activity. In vitro promoter activity as well
as in vivo gene expression of the 6A allele has
approximately 50% less promoter strength than that
of the 5A allele.10,11 This lower level of proteolytic
activity would favor extracellular matrix deposition
because of decreased degradation. Three independent
studies found that Caucasian patients carrying the
6A6A genotype had more progress ion of
angiographically detectable lesions in documented
coronary artery disease.12–14 In contrast, increased
focal expression and activity of MMP-3 by the 5A
allele predispose to plaque instability and rupture in
the presence of a high atherosclerotic burden
associated with acute coronary syndrome.15,16 Thus,
stromelysin-1 genetic variations contribute to
heterogeneity in the presentation and natural history
of atherosclerosis.17 However, little information on
the Chinese population has been reported.
Accordingly, the purpose of this study was to
investigate the allele frequency of stromelysin-1
promoter gene polymorphism (5A/6A) and its
possible influences on restenosis after coronary stent
implantation in the Chinese population in Taiwan.
Methods
Patient population
The study initially had 435 enrolled patients who
underwent successful bare metal stent implantation
between January 1999 and July 2002. All stents were
implanted using high-pressure adjunct balloon
angioplasty (* 12 atm) to achieve the targeted stent
expansion. All subjects received 300–500 mg
ticlopidine (or 75 mg clopidogrel) and 100–325 mg
aspirin per day after coronary intervention for at least
3 months. All patients gave written informed consent
for the intervention, follow-up angiography and
genotype determination. Ninety-one patients (21%)
who did not repeat angiography systematically because
of advanced age, impaired general condition, or patient
preference (without symptoms) were excluded.
Therefore, a total of 344 patients were included in the
final analysis. The study protocol conformed to the
Declaration of Helsinki and was approved by our
institution’s ethics committee.
Determination of stromelysin-1 genotypes
All blood was collected in Vacutainer EDTA tubes in
an overnight fasting state. The stromelysin-1 promoter
genotype was analyzed by polymerase chain reaction
(PCR) amplification of the genomic DNA extracted
from lymphocytes of the stored blood. The sense and
anti-sense primers were 5’-GGTTCTCCATTCCTT-
TGATGGGGGGAAAGA-3’ and 5’-CTTCCTGGA-
ATTCACATCACTGCCACCACT-3’, respectively.
The amplification protocol consisted of an initial
denaturation segment at 95°C for 5 minutes.
After this, each cycle consisted of 3 segments
(94°C for 30 seconds, 61°C for 30 seconds and 72°C
for 1 minute). The cycle was repeated 30 times,
followed by an additional extension at 72°C for 5
minutes. The amplified fragments were cut with
endonuclease TthIII I, which can recognize the
sequence 5’-GACNNNGTC-3’, in which the
DNA template contains 5As (but not 6As) at the
polymorphic site. These fragments were then
electrophoresed in 4% agarose gel and stained with
ethidium bromide.
Angiographic assessment
Quantitative computer-assisted angiographic analysis
was performed off-line on angiograms obtained just
before and immediately after coronary intervention,
and at follow-up, using the automated edge-
detection system with CAAS II (Pie Medical,
Maastricht, The Netherlands). Operators were
unaware of the patients’ genotypes. Identical
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projections were used for all assessed angiograms.
The angiographic parameters determined were
interpolated reference diameter, lesion length,
minimal lumen diameter, and percent diameter
stenosis. Late lumen loss was calculated as the
difference between the final post-stenting minimal
lumen diameter and minimal lumen diameter
measured at follow-up angiography. Lesion
morphology was assessed according to the modified
American College of Cardiology/American Heart
Association grading system, and classified as type A,
B1, B2, or C.18 Lesions of types B2 and C were
considered complex lesions. Angiographic restenosis
was defined as diameter stenosis of 50% or more on
follow-up examination. Patients who had more than
1 lesion treated were defined as having restenosis if
at least 1 stented vessel fulfilled the criteria for
restenosis.
Statistical analysis
Discrete variables were expressed as counts or
percentages, and continuous variables were expressed
as mean ± standard deviation. The Chi-squared statistic
with Yates’ correction, or Fisher’s exact test when
appropriate, was used to test associations of discrete
variables. Student’s t test and 1-way ANOVA were
used to test differences between mean values of
continuous variables. Potential associations among
clinical, angiographic, or procedural factors, genotypes
and restenosis were tested by univariate analysis
(Student’s t or Chi-squared tests). All variables
associated with a p of less than 0.1 were entered into
a stepwise multivariate logistic regression model to
identify independent predictors. The odds ratios (OR)
and 95% confidence intervals (CI) were presented for
the final multivariate model. Data were prospectively
collected and analyzed using SPSS version 11.0 (SPSS
Inc, Chicago, IL, USA). A p value of less than 0.05 was
considered to be statistically significant.
Results
The main baseline characteristics of the 344 patients
(301 men, 43 women; mean age, 67 years; age range,
27–90 years) are listed in Table 1. The stromelysin-1
promoter genotypes 5A5A, 5A6A, and 6A6A were in
12 (3.5%), 78 (22.7%), and 254 (73.8%) patients,
respectively. Thus, the frequency of the 6A allele was
0.85. There were no significant differences among the
3 genotypes in terms of baseline clinical characteristics,
lesion variables before coronary intervention, and
procedural parameters.
Predictors of ISR
The clinical, angiographic and procedural features,
and allele and genotype frequencies according to
angiographic restenosis among the whole population
are summarized in Table 2. Overall, 120 patients had
angiographic restenosis (34.9%). There was no
significant difference between the non-6A6A and 6A6A
groups (28.9% and 37.0% respectively, p = 0.165).
Hypercholesterolemia, complex lesions (B2 or C),
lesion length, minimal lumen diameter, reference vessel
diameter immediately before and after, and diameter
stenosis were identified as potential risk factors for ISR
by univariate analysis. These factors were entered into
a multivariate logistic regression model; lesion
complexity (OR, 2.67; 95% CI, 1.55–4.61; p < 0.001),
reference vessel diameter before angioplasty (OR, 0.35;
95% CI, 0.19–0.64; p = 0.001), and minimal diameter
stenosis (OR, 0.43; 95% CI, 0.23–0.80; p = 0.08)
emerged as independent predictors of ISR.
Subgroup analyses
We separately examined the putative effect of the
subgroup analyses to determine whether there were
associations between genotype and ISR regarding age
(< 60 or * 60 years), gender, hypertension, diabetes
mellitus, smoking, hypercholesterolemia, history of
myocardial infarction, presence of unstable angina
pectoris on admission, number of diseased vessels, and
target coronary vessel. The subgroup analysis revealed
that stromelysin-1 polymorphism had a significant
influence on patients with unstable angina or stable
angina undergoing stent implantation. The other
subgroup analyses failed to show significance.
Table 3 shows a significantly higher ISR rate for
the 6A6A genotype in patients with stable angina
(p = 0.029). Furthermore, when a multivariate logistic
regression model was built for this group with stable
angina, it was still found that homozygosity for the
6A6A genotype was an independent predictor of ISR
(OR, 2.57; 95% CI, 1.22–5.41; p = 0.013). On the
other hand, Table 4 shows that patients with the
5A5A or 5A6A genotypes and with unstable angina
had the highest ISR rates. Compared with those with
stable angina, there was a significant difference (48%
vs 21.5%, p = 0.013).
Discussion
The results of the present study showed that
polymorphism of the stromelysin-1 promoter 5A/6A
gene does not correlate with the occurrence of ISR in
the whole study population. However, subgroup
Stromelysin-1 gene polymorphism and restenosis
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analysis by patients with angina status revealed that
there were significantly different effects. Recently,
5A/6A polymorphism and angiographic outcome in
patients who underwent stent implantation were
examined by Humphries et al19 and Hoppmann et al.20
No statistical differences in ISR rates among the whole
study population were found. That said, the clinical
factors of their study populations, such as age,
distribution of risk factors, lesion complexity, and
ethnic population, were different from those in our
study. In addition, the abovementioned studies did
not further explore whether associations existed using
subgroup analyses. Furthermore, interaction between
stromelysin-1 gene variation and environmental factors
plays an important role in clinical significance.21–23
Therefore, further subgroup analysis for ISR provided
valuable information regarding whether it influenced
outcomes after coronary stenting.
The reported prevalence of the 5A allele in Caucasians
varies from 40% to 50%.11–15 In this study, the frequency
of the 5A allele in the promoter region of stromelysin-
1 was only 15%. This allele frequency was similar to that
in Chinese patients with normal coronary angiograms
in our laboratory (unpublished data, frequency of the
5A allele was 17% and that of the 6A allele was 83%). It
was compatible with the Hardy-Weinberg equilibrium.
Interestingly, the distribution of the genotype in the
Chinese group is similar to that in a Japanese ethnic
group16 and the subjects in the study of Liu et al.23 These
data support the hypothesis that genetic mutations are
specific to particular ethnic groups.
Disruption of culprit coronary stenoses in patients
who have undergone coronary angioplasty causes
inflammatory responses. It triggers more expression
of stromelysin-1 by inflammatory cells over unstable
coronary plaques than stable plaques. In this regard,
Table 1. Baseline characteristics of 344 patients with 5A/6A polymorphism of the stromelysin-1 genotype*
5A5A 5A6A 6A6A
p
(n = 12) (n = 78) (n = 254)
Age (yr) 67.4 ± 8.4 66.9 ± 9.5 66.8 ± 11.3 0.980
Men 10 (83.3) 69 (88.5) 222 (87.4) 0.879
Body mass index 26.5 ± 2.2 26.6 ± 3.2 25.9 ± 3.3 0.247
Hypertension 9 (75.0) 52 (66.7) 231 (90.9) 0.840
Diabetes mellitus 3 (25.0) 26 (33.3) 79 (31.1) 0.829
Hypercholesterolemia 5 (41.7) 26 (33.3) 80 (31.5) 0.743
Previous myocardial infarction 1 (8.3) 26 (33.3) 89 (35.0) 0.160
Current smoker 1 (8.3) 10 (12.8) 39 (15.4) 0.707
Angina status on admission 0.515
Stable 10 (83.3) 55 (70.5) 173 (68.1)
Unstable 2 (16.7) 23 (29.5) 81 (31.9)
Number of diseased vessels 0.100
Single vessel disease 1 (8.3) 28 (35.9) 100 (39.4)
Double vessel disease 4 (33.3) 29 (37.2) 90 (35.4)
Triple vessel disease 7 (58.3) 21 (26.9) 64 (25.2)
Stented coronary vessel 0.275
LAD 6 (50.0) 43 (55.1) 122 (48.0)
LCX 2 (16.7) 7 (9.0) 51 (20.1)
RCA 4 (33.3) 28 (35.9) 81 (31.9)
ACC/AHA classification 0.658
A 2 13 42
B1 4 21 70
B2 4 25 103
C 2 19 39
Lesion length (mm) 11.8 ± 7.2 14.1 ± 7.2 14.0 ± 6.4 0.549
Reference diameter (mm) 2.88 ± 0.68 2.86 ± 0.45 2.89 ± 0.42 0.750
Minimal lumen diameter (mm) 0.77 ± 0.81 0.52 ± 0.37 0.54 ± 0.73 0.189
Diameter stenosis (%) 80.2 ± 14.6 81.5 ± 14.0 81.5 ± 13.6 0.956
Acute gain (mm) 2.33 ± 0.43 2.32 ± 0.64 2.28 ± 0.94 0.939
*Data are presented as mean ± standard deviation or number (%) of patients. ACC/AHA = American College of Cardiology/American Heart Association;
LAD = left anterior descending coronary artery; LCX = left circumflex coronary artery; RCA = right coronary artery.
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Table 2. Univariate analysis for angiographic predictors of in-stent restenosis in the 344 study patients*
Restenosis No restenosis
p
(n = 120) (n = 224)
Demographics
Age (yr) 66.0 ± 12 67.2 ± 10.1 0.313
Male 104 (86.7) 197 (87.9) 0.732
Body mass index 26.1 ± 3.3 26.1 ± 3.2 0.921
Risk factors
Hypertension 81 (67.5) 150 (67.0) 0.920
Diabetes mellitus 38 (31.7) 70 (31.3) 0.137
Hypercholesterolemia 30 (25.0) 81 (36.2) 0.035
Previous MI 45 (37.5) 71 (31.7) 0.278
Current smoker 23 (19.2) 27 (12.1) 0.074
Angina status on admission 0.140
Stable angina 77 (64.2) 161 (71.9)
Unstable angina 43 (35.8) 63 (28.1)
Coronary angiography
Multivessel disease 78 (65.0) 137 (61.2) 0.483
Stented coronary vessels 0.057
LAD 63 (52.5) 108 (48.2)
LCX 13 (10.8) 47 (21.0)
RCA 44 (36.7) 69 (30.8)
Lesion type† < 0.001
Simple (A/B1) 26 (21.7) 111 (49.6)
Complex (B2/C) 94 (78.3) 113 (50.4)
RD pre-PCI (mm) 2.76 ± 0.39 2.95 ± 0.44 < 0.001
% DS pre-PCI 84.9 ± 13.0 79.6 ± 13.7 0.01
MLD pre-PCI 0.41 ± 0.36 0.62 ± 0.47 < 0.001
Lesion length (mm) 16.0 ± 6.7 12.8 ± 6.3 < 0.001
RD post-PCI (mm) 2.70 ± 0.45 2.93 ± 0.45 < 0.001
Acute gain (mm) 2.23 ± 0.56 2.32 ± 0.99 0.341
Alleles
5A 26 (21.7) 64 (28.6) 0.165
6A 117 (97.5) 215 (96.0) 0.465
Genotypes 0.364
5A5A 3 (2.5) 9 (4.0)
5A6A 23 (19.2) 55 (24.6)
6A6A 94 (78.3) 160 (71.4)
*Data are presented as mean ± standard deviation or number (%) of patients; †simple lesions were defined as type A or B1 and complex lesions
were defined as type B2 or C according to the modified American College of Cardiology/American Heart Association grading system. DS = diameter
stenosis; LAD = left anterior descending coronary artery; LCX = left circumflex coronary artery; MI = myocardial infarction; MLD = minimal luminal
diameter; PCI = percutaneous coronary intervention; RCA = right coronary artery; RD = reference diameter.
Table 3. Distribution of the 5A/6A polymorphism in a subgroup of patients with unstable or stable angina
Patients with unstable angina Patients with stable angina
Restenosis No restenosis
p
Restenosis No restenosis
p
(n = 43) (n = 63) (n = 77) (n = 161)
Genotypes, n (%)
5A5A + 5A6A 12 (27.9) 13 (20.6) 0.387 14 (18.2) 51 (31.7) 0.029
6A6A 31 (72.1) 50 (79.4) 63 (81.8) 110 (68.3)
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there is an exaggeration of smooth muscle cell
recruitment, migration and proliferation at the neo-
intima during the early weeks, which produces inti-
mal hyperplasia among patients with unstable angina
undergoing stent implantation.24,25 Previous data
revealed more expression and activity of stromelysin-1
in patients with the 5A allele.10,11 Taken together, these
support our results that patients with unstable angina
and the 5A5A or 5A6A genotype had the highest ISR
rate. Based on this, we speculate that patients with
unstable angina, especially those with the 5A5A or
5A6A genotype, may benefit from anti-inflammatory
agents or inhibitors of MMPs to inhibit the early in-
flammatory response and reduce neointimal hyperplasia.
In contrast to the early tissue response consisting
of aggregated inflammatory cells and loosely struc-
tured matrix components, the late tissue response
(proliferation phase) consists of large components of
extracellular matrix and loose arrays of smooth muscle
cells.26 On the basis of the idea that lower stromelysin-
1 expression in patients with the 6A6A genotype
causes matrix accumulation and thickening of the
neointima,10,11 we speculate that patients carrying the
6A6A genotype with stable angina would have more
pronounced extracellular matrix accumulation by
smooth muscle cells in the late proliferative phase of
neointima and have higher ISR rates compared with
non-6A6A genotype patients with stable angina.
Further studies are needed to confirm this
hypothesis in independent populations. Also, it is
necessary to investigate the precise timing and location
of the influence of stromelysin-1 expression in the
different stages (early and late phases) of ISR among
5A/6A genotype patients with different angina status.
The potential role of 5A/6A polymorphism in the
promoter of the stromelysin-1 gene in the initiation or
progression of ISR may be explored by direct
measurements of stromelysin-1 levels and degradation
and synthesis of extracellular matrix in tissue removed
at surgery from patients. This can boost the develop-
ment of antirestenosis strategies such as MMP inhi-
bitors or antisense oligonucleotide technology.
Table 4. Association between 5A/6A polymorphism and angina status for patients with in-stent restenosis
Genotypes Angina status Restenosis, n (%) No restenosis, n (%) p
5A5A + 5A6A Unstable 13 (52.0) 12 (48.0) 0.013
Stable 14 (21.5) 51 (78.5)
6A6A Unstable 31 (38.4) 50 (61.7) 0.440
Stable 63 (36.4) 114 (63.6)
Recently, the advent of drug-eluting stents (DES)
containing the immunosuppressive agent rapamycin
or the antimitotic agent paclitaxel has shown encour-
aging reductions in ISR (4.0–8.9%).27,28 There is,
at present, no information regarding the relationship
between genetic profile and restenosis in patients who
received DES implantation. However, routine use of
DES in all patients during PCI is financially prohibitive.
It is worthwhile to analyze the genetic risk profile of an
individual patient to identify who will derive particular
benefit from the use of DES. In addition, smaller
vessels, longer lesions with complex morphologies,
and ISR lesions were identified as predictors in patients
with high-risk post-DES restenosis (10.3–19.6%).27
Thus, further investigation to identify patients with
these risk factors and stromelysin-1 genotyping to
adjust drug doses for DES may help to overcome these
limitations in the future.
Some limitations of this study should be mentioned.
First, we achieved a follow-up angiography rate of
79%. Previous trials on restenosis have reported similar
angiographic follow-up rates. Second, the genetic
heterogeneity of complex processes such as ISR is not
likely to depend on a single but rather on several
polymorphisms that may cluster in the same gene
locus or, more probably, in different loci. Third,
intravascular ultrasound, which provides more detailed
information than quantitative computer analysis, was
not available for this study.
In conclusion, the frequency of the 5A allele of the
stromelysin-1 gene promoter is low in the Chinese
population. There were no significant differences in
the whole population of patients receiving stent
implantation. However, subgroup analyses revealed
that among patients suffering from unstable angina
who underwent stent implantation, the non-6A6A
genotype group had the highest ISR rate. Also, of
patients suffering from stable angina, the 6A6A
genotype group had a higher ISR rate. These results
merit further study to identify patients’ genetic profile
and investigate which MMP inhibitors or DES are
more effective among those at risk.
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